Tech Company Financing Transactions
Biosplice Therapeutics Funding Round
Biosplice Therapeutics, based in San Diego, secured $120 million from aMoon Partners, Eventide Asset Management and Sands Capital Management.
Transaction Overview
Company Name
Announced On
4/16/2021
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
aMoon Partners (Gur Roshwalb)
Eventide Asset Management (Joy Ghosh)
Proceeds Purpose
This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9360 Towne Centre Dr.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Osman Kibar
Chief Executive Officer
Cevdet Samikoglu
Chief Financial Officer
Erich Horsley
Chief Medical Officer
Darrin Beaupre
Chief Medical Officer
Yusuf Yazici
Chief Operating Officer
Philippe Marchand
Chief Scientific Officer
Michael White
VP - General Counsel
Arman Oruc
Browse more venture capital transactions:
Prev: 4/16/2021: Canvas Robotics venture capital transaction
Next: 4/16/2021: Encamp venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs